[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurofibromatoses\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurofibromatoses":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100657933","neurocutaneous-syndromes-in-children-prevalence-and-clinical-characteristics-100657933",false,"NCT07843823","Neurocutaneous Syndromes in Children: Prevalence and Clinical Characteristics","Prevalence, Clinical Characteristics, and Management of Neurocutaneous Syndromes in Children","Inclusion Criteria:\n\n* Age from birth to 18 years\n* Diagnosis of neurocutaneous syndrome according to established clinical and\u002For genetic diagnostic criteria\n* Written informed consent from parents or legal guardians\n\nExclusion Criteria\n\n* Uncertain diagnosis\n* Incomplete medical records\n* Refusal of parents or legal guardians to participate","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This cross-sectional study aims to determine the prevalence, clinical characteristics, and management patterns of neurocutaneous syndromes among children attending the Pediatric Neurology Unit at Assiut University.",[24,25,26,27],"Sturge-Weber Syndrome","Neurocutaneous Syndromes","Neurofibromatoses","Tuberous Sclerosis",[25,29,30,31,24,32],"Phakomatoses","Neurofibromatosis type 1","Tuberous Sclerosis Complex","Assiut","NOT_YET_RECRUITING","2026-09-21",{"date":36,"type":37},"2026-09-28","ACTUAL",{"date":39,"type":20},"2026-09-20",{"date":41,"type":20},"2028-02-20",{"name":43,"class":44},"Assiut University","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100313349","the-neurofibromatosis-associated-tumor-biobank-100313349","NCT03359304","The Neurofibromatosis-associated Tumor Biobank","Establishment of Neurofibromatosis-associated Tumours Biobank for Future Genomic-based Research Aiming at Improved Outcome Prediction","Inclusion Criteria:\n\nProband Inclusion criteria: A diagnosis or suspected diagnosis of neurofibromatosis-associated tumor Family member inclusion criteria: Biological parents and full biological siblings of a case diagnosed with neurofibromatosis-associated tumor\n\nExclusion Criteria:\n\nnon-asian",{"count":53,"type":20},300,"Neurofibromatosis-associated Tumor is very rare bone tumor. The investigator set up the biobank to ensure every patient has the chance to participate in future research",[26],[57],"bone tumor","2017-11-29",{"date":60,"type":37},"2017-12-02",{"date":62,"type":20},"2018-03-01",{"date":64,"type":20},"2028-03-01",{"name":66,"class":44},"Ren tingting"]